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The Regulation of Steroid Action by Sulfation
and Desulfation
Jonathan W. Mueller, Lorna C. Gilligan, Jan Idkowiak, Wiebke Arlt, and Paul A. Foster
Centre for Endocrinology, Diabetes, and Metabolism, Institute of Metabolism and Systems Research, University of
Birmingham, Birmingham B15 2TT, United Kingdom
Steroid sulfation and desulfation are fundamental pathways vital for a functional vertebrate endocrine system.
After biosynthesis, hydrophobic steroids are sulfated to expedite circulatory transit. Target cells express trans-
membrane organic anion-transporting polypeptides that facilitate cellular uptake of sulfated steroids. Once
intracellular, sulfatases hydrolyze these steroid sulfate esters to their unconjugated, and usually active, forms.
Because most steroids can be sulfated, including cholesterol, pregnenolone, dehydroepiandrosterone, and
estrone, understanding the function, tissue distribution, and regulation of sulfation and desulfation processes
provides significant insights into normal endocrine function. Not surprisingly, dysregulation of these pathways
is associated with numerous pathologies, including steroid-dependent cancers, polycystic ovary syndrome, and
X-linked ichthyosis. Here we provide a comprehensive examination of our current knowledge of endocrine-
related sulfationanddesulfationpathways.Wedescribe the interplaybetweensulfatasesand sulfotransferases,
showing how their expression and regulation influences steroid action. Furthermore, we address the role that
organic anion-transporting polypeptides play in regulating intracellular steroid concentrations and how their
expression patterns influence many pathologies, especially cancer. Finally, the recent advances in pharmaco-
logically targeting steroidogenic pathways will be examined. (Endocrine Reviews 36: 526–563, 2015)
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I. Introduction
Sulfation and desulfation are vital biological processesthat regulate steroidogenesis and thus, steroid hor-
mone action in a variety of tissue (Figure 1). Controlled by
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Adiol, 5-androstenediol; APS, adenosine-5-phosphosulfate; AR, androgen receptor;
BCRP, breast cancer-resistant protein; BPH, benign prostate hyperplasia; BPNT1, 3,5-
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androsterone; DHEAS, DHEA sulfate; DHT, dihydrotestosterone; DHTS, DHT sulfate; E1,
estrone; E1S, E1 sulfate; E2, estradiol; E2S, E2 sulfate; ER, estrogen receptor; FGE, FGly-
generating enzyme; FGly, formylglycine; GAG, glycosaminoglycan; GC, gas chromatog-
raphy; gPAPP, Golgi-resident PAP phosphatase; HRT, hormone replacement therapy;
17HSD, 17-hydroxysteroid dehydrogenase; LC, liquid chromatography; LC-MS/MS, LC-
tandem MS; MRP, multidrug-resistant protein; MS, mass spectrometry; MSD, multiple
sulfatase deficiency; OATP, organic anion-transporting polypeptide; PAP, 3-phospho-
adenosine-5-phosphate; PAPS, 3-phospho-adenosine-5-phosphosulfate; PCOS, poly-
cystic ovary syndrome; PI3, phosphatidylinositol 3; PXR, pregnane X receptor; SLC, solute
carrier; STS, steroid sulfatase; SULT, sulfotransferase; SUMF1, sulfatase-modifying factor 1;
TM, transmembrane domain; XLI, X-linked ichthyosis.
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two distinct enzyme families, the sulfatases and the sulfo-
transferases (SULTs), these processes are intimately in-
volved in the hydrolysis and esterification of sulfate
groups to alkyl (eg, dehydroepiandrosterone [DHEA])
and aryl (eg, estrone [E1]) steroids. As early as the 1940s,
steroids were identified as one of the major classes of
biomolecules that could be sulfated (1–3). Chemically, it
is possible to attach a sulfate to each and every hydroxyl
groupof a steroid, and taking into account the astonishing
substrate promiscuity of the various sulfotransferase en-
zymes, many different sulfated steroids are detected ana-
lytically in biological samples (4). Historically, sulfated
steroids were considered to be metabolic end products
because their increased water solubility expedites excre-
tion.However, over the past 20 years, awealth of research
demonstrates that sulfated steroids, such asDHEA sulfate
(DHEAS) and E1 sulfate (E1S), can act as circulating res-
ervoirs for the peripheral formation of bioactive hor-
mones. Therefore, an understanding of how sulfation and
desulfation processes are regulated and dysregulated pro-
vides key insights into physiological and pathophysiolog-
ical endocrine control. This review examines our current
understanding of sulfation and desulfation steroid path-
ways, including the intracellular influx and efflux of sul-
Figure 1.
Figure 1. Predominance for steroid sulfation or desulfation in endocrine and selected nonendocrine human tissues. Sulfation pathways dominate in
the healthy brain, colon, adrenal, and kidney. The colon and kidney sulfate steroids to expedite excretion. The adrenal synthesizes DHEA, which is
subsequently sulfated to increase water solubility and allow circulatory transport. The brain favors sulfation, although this is primarily due to the
role of pregnenolone sulfate as a neurosteroid. In the liver, a so-called “futile-loop” of DHEA/DHEAS, E1/E1S, and E2/E2S occurs, as well as other
steroids. Because sulfated forms of these steroids persist longer in the circulation due to greater half-lives, this accounts for their higher circulating
concentrations compared to their nonsulfated forms. Desulfation, via STS, dominates in the breast, ovary, prostate, testis, placenta (not shown),
and uteri (not shown). In breast and ovarian tissue, E1S uptake occurs through OATPs (see Section IV), where it is desulfated by STS to form E1,
and subsequently E2 via 17HSDs. In the prostate and testis, circulating DHEAS can also be transported into the cell via OATPs, desulfated by
STS, and then metabolized to androgens such as T and DHT, which can then enter the circulation.
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fated steroids via the organic anion transporter proteins
(see Section IV), the role of these pathways in disease (see
SectionsVandVI), and thepotential topharmacologically
target these pathways for therapeutic gain (see Section
VII).
A. Steroid analysis
The era of steroid analysis via immunoassay is drawing
to a close as these unspecific assays are replaced by high-
throughput, specific, sensitive mass spectrometry (MS)
analyses (5). The inherent problem of immunoassays is
their poor specificity due to antibody cross-reactivity,
which hampers both enzyme immunoassay and RIA ap-
proaches. With regard to the measurement of estradiol
(E2), this problemwas identified over 25 years ago (6) and
more recently in human plasma samples (7). However,
with the increasing clinical and laboratory demand for
steroidmeasurements, cheapRIA kits emerged as popular
one-step kits andmultiplex assays in the 1980s and1990s.
These “direct” immunoassay kits sacrificed accuracy for
speed and economy (8).
Gas chromatography (GC)-MS, coupled with either
electron impact ionization or chemical ionization, is sen-
sitive and specific, but it requires extensive sample cleanup
aswell asmultistep deconjugation and derivatization pro-
cedures. Thus, it is liquid chromatography (LC)-MS or
LC-tandem MS (LC-MS/MS) that after pioneering work
in the 1990s (9) is becoming the reference method for the
analysis of both sulfated and nonsulfated steroids in clin-
ical laboratories, due to its fast turnaround time and high
accuracy. Indeed, a recent statement by The Endocrine
Society had attempted to implement a policy toward in-
troducing LC-MS as the diagnostic standard for publica-
tion of steroid measurements (8), although this position
was later relaxed because many laboratories do not have
the technology to achieve such accurate analysis (10). Ta-
ble 1 shows plasma reference ranges for nonsulfated and
sulfated steroids in adult men, premenopausal adult
women, and postmenopausal women.
The measurement of sulfated steroids can be straight-
forward, as conjugated steroids easily ionize resulting in
greater LC-MS sensitivity. RIAs do exist that canmeasure
sulfated steroids, as mentioned above cross-reactivity and
the lability of the sulfate group, make these methods un-
reliable.Advances employingultrahighpressureLCquad-
rapole time-of-flightMScannowdetect a rangeof sulfated
and glucuronidated steroids simultaneously in human
urine with similar sensitivity to GC-MS (11). With regard
toplasma, recently a rapidLC-MS/MSprocedurehasbeen
designed involving diethylether extraction from plasma,
purification by immunosorbents containing specific anti-
bodies against E1S, followed by LC-MS/MS using electro-
spray ionization. This sample preparation markedly im-
proved the sensitivity of LC-MS/MS for E1S (12). Others
have utilized LC-MS/MS with electrospray ionization to
detect other sulfated steroids such as dihydrotestosterone
sulfate (DHTS) and 3-hydroxy-5-androstane-17-sul-
fate simultaneously (13). However, the main difficulty
withmeasuringmost sulfated steroids lies with the lack of
availability of appropriate reference standards, making
measurements impossible to accurately quantify.
II. Steroid Sulfatases
A. Molecular overview and functionality
The sulfatase enzyme family catalyzes the hydrolysis of
sulfate ester bonds fromawide rangeof substrates.Within
this family, 17 genes havebeen identified inhumans,many
associatedwith genetic disorders (14).Of these, three have
Table 1. Approximate Estimates of Plasma Concentrations of Steroids and Their Sulfates in Human Adults
Steroid Males Premenopausal Females Postmenopausal Females
Cholesterol 0–1 nmol/L 0–1 nmol/L 0–1 nmol/L
Cholesterol sulfate 0–3 mol/L 0–3 mol/L 0–3 nmol/L
Pregnenolone 1–15 nmol/L 1–15 nmol/L 1–15 nmol/L
Pregnenolone sulfate 200–1000 nmol/L 100–1000 nmol/L 10–500 nmol/L
DHEA 10–25 nmol/L 5–30 nmol/L 2–20 nmol/L
DHEAS 2–10 mol/L 1–8 mol/L 1–6 mol/L
Androsterone 2–4 nmol/L 2–4 nmol/L
Androsterone sulfate 0–5 mol/L 0–1 mol/L
E1 30–140 pmol/L 15–500 pmol/L 10–120 pmol/L
E1S 2–4 nmol/L 2–5 nmol/L 0.5–2 pmol/L
E2 20–40 pmol/L 5–1000 pmol/L 5–80 pmol/L
Progesterone 0–0.4 nmol/L 0–80 nmol/L 0–0.4 nmol/L
T 5–25 nmol/L 0.2–2 nmol/L 0.2–1 nmol/L
DHT 850–3500 pmol/L 80–1300 pmol/L 30–650 pmol/L
DHTS 50–100 nmol/L
Where values are missing, not enough sufficient evidence is available to provide accurate estimates.
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their crystal structure determined: arylsulfatase A, B, and
C (the latter also known as steroid sulfatase [STS]). Aryl-
sulfatases A and B are both water soluble and involved in
thehydrolysis of cerebroside-3-sulfate and thebreakdown
of glycosaminoglycans (GAGs), respectively; thus, neither
is involved in steroid pathways. In contrast, STS has been
shown to be the primary enzyme involved in steroid des-
ulfation (15) and therefore is themain focus in this review.
The principal hormone substrates for STS are E1S,
DHEAS, pregnenolone sulfate, and cholesterol sulfate,
and therefore this enzyme represents one of the major
pathways in regenerating biologically active steroids in
both steroidogenic and nonsteroidogenic tissues. DHEA
and E1 circulate predominantly in their inactive sulfated
forms, DHEAS and E1S, respectively. Cells can transport,
via organic anion-transporting polypeptides (OATPs; see
Section IV), circulating hydrophilic sulfated steroids, such
as DHEAS and E1S, for intracellular desulfation by STS
and subsequent generation of androgenic and estrogenic
steroids.
Structurally, STS has a hydrophobic domain and is a
membrane-bound microsomal enzyme, mainly localized
in the rough endoplasmic reticulum (16, 17). The 10 ex-
ons- spanning STS gene is located on the short arm of
chromosome X and mapped in Xp22.3-Xpter (17–19). It
escapes X-inactivation (20) with a nonexpressed Y-linked
homolog in man (18). It is thought that STS is glycosy-
lated,with its three-dimensional structure crystallography
showing it to be a monomer of a “mushroom-like” shape
with two hydrophobic antiparallel -helices protruding
from a spherical molecule (21, 22). This 40 Å-long hy-
drophobic stem is most likely embedded in the luminal
membrane of the endoplasmic reticulum. Opening beside
it is a long narrow pocket with the enzyme reaction site
lying at the base, suggesting that the product has to travel
through the endoplasmic reticulum membrane (23).
STS is expressed as a membrane-associated precursor
with a molecular mass of 63 kDa and asparagine-linked
oligosaccharide chains. These chains are cleaved by endo-
glucosaminidase H, creating a final size of 61 kDa with a
half-life of 4 days (24). STS can undergo various post-
translational modifications; it holds four potential N-gly-
cosylation sites; however, digestion by endoglycosidaseH
andendoglucosaminidaseHshowed that only two (Asn47
and Asn259) are used (25, 26). Supporting this, Stengel et
al (27) found that although all four of the N-linked sites
are glycosylated to some extent, only mutations in two
major glycosylation sites, againat asparagines47and259,
decreased activity. Anothermodification is the conversion
of C75 to formylglycine (FGly) (see Section II.A,1) and
further hydration forms the gem-diol hydroxylformylgly-
cine with a bound sulfate in the resting state (28).
Disease resulting from impaired STS activity, such as
X-linked ichthyosis (XLI), is most often due to large de-
letions of the gene (80–90%). Alternatively, in some XLI
patients, six-point mutations have been identified, all
abolishing STS activity (29–31). Five of the point muta-
tions lead to nonconservative amino acid changes, and the
sixth is a frameshift mutation. Interestingly, these muta-
tions are all within 105 residues of each other in the C-
terminal half. Two are even on the same amino acid, 372,
changing tryptophan to either arginine or proline. The
others are an arginine for tryptophan at amino acid 444,
a tryptophan for a cysteine at 446, a cysteine substitute for
a leucine at 341, and an arginine for serine at 419. This
close accumulation of mutations suggests that this as an
area crucial for STS activity (32, 33). Furthermore, arti-
ficially truncating N or C termini of the STS enzyme does
not have any effect on protein synthesis and degradation,
when transfected into COS-1 cells, however, there was
reduction in activity (34). Thus, when coexpressed with
wild-type STS, C-terminal STS mutants have a dominant
negative effect.
1. Sulfatase-modifying factors
The molecular mechanisms underlying STS catalytic
activity are highly conserved among different human sul-
fatase enzymes (16, 35). A cysteine residue resides in the
catalytic center of all sulfatases, which is post-translation-
ally modified to form a FGly residue (Figure 2). FGly is
catalytically active and “attacks” the sulfate moiety of
substrates; it is essential to bind the substrate and also to
hydrolyze the sulfate ester bond (36, 37).
Modification of the cysteine to form FGly is mediated
by the coenzyme FGly-generating enzyme (FGE), which is
encoded by the sulfatase-modifying factor 1 (SUMF1)
gene. FGE, a glycosylated enzyme that, like STS, resides in
the endoplasmic reticulum, can be secreted by cells (38).
Intriguingly, FGE can thus act in a paracrine fashion be-
cause it can be taken up by neighboring cells as a func-
tional protein and increase intracellular sulfatase activity
(39). The importance of this process in regulating STS
activity and steroid output is currently unknown.
Mutations in SUMF1 cause multiple sulfatase defi-
ciency, a rare and fatal autosomal recessive disorder char-
acterized by absent activity of all sulfatase enzymes (see
Section V.A) (40, 41). A paralog of SUMF1, SUMF2, has
been cloned in vertebrates due to its sequence homology to
SUMF1 (42, 43). SUMF2 lacks the crucial catalytic do-
main present andhighly conserved in SUMF1, and the role
of SUMF2 in the process of post-translational modifica-
tion of sulfatases is, at present, unresolved.
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B. STS cellular and tissue distribution
STS is a membrane-bound protein primarily localized
in the lumen of the endoplasmic reticulum (23), although
it has also been found in Golgi cisternal, trans-Golgi re-
ticulum, plasma membranes, and elements of the endo-
cytic pathway (44). In 1965, Warren and French (45) ex-
amined STS tissue distribution and found virtually
ubiquitous expression in human tissues, with placenta
demonstrating the greatest mRNA and activity. These
findings have been substantiated bymany research groups
using various techniques, such as immunohistochemistry,
biochemical analysis, and real-time PCR, analyzing amul-
titude of tissues including testis, ovary, adrenals, prostate,
skin, brain, endometrium, kidney, thyroid, pancreas, co-
lon, aorta, bone, and lymphocytes (19, 35, 46), which all
show STS activity.
From gestation and throughout life, STS activity remains
imperative to both genders for tissue-specific steroid hor-
moneproductionandregulation. Inpremenopausalwomen,
the main source of active E2 is the ovaries, whereas E1 is
formedmostly inperipheral tissues,eg, fat.However, inpost-
menopausal women and men, E2 is
metabolized from adrenal steroid pre-
cursors at extragonadal sites such as
breast and fat. The active estrogens
canbegeneratedby twoenzymes, aro-
matase and sulfatase. STS desulfates
E1S to E1, followed by reduction to E2
via reductive 17-hydroxysteroid de-
hydrogenase (17HSD) activity. Aro-
matase converts androstenedione and
T to E1 and E2, respectively. Of note,
androstenedione is synthesized from
the precursors DHEA and DHEAS,
which circulates at very high concen-
trations compared to other steroids
(see Table 1). STS desulfates DHEAS,
and thus STS also plays a role in liber-
ating androgens for aromatization
(47).
C. The regulation of STS
STS tissue activity fluctuates de-
pending on physiological conditions,
but exactly which factors regulate
these changes remains unknown. For
example, STS activity is higher in leu-
kocytes inthethirdtrimesterofhuman
pregnancy compared to nonpregnant
females andadultmales (48), an effect
possibly regulated by elevated FSH
concentrations (49). Furthermore,
and again asmeasured in leukocytes,
STS activity changes throughout puberty, differing be-
tween males and females and being at its highest in pre-
pubertal females (50). STS is also frequently increased in
various malignant tissues, such as in breast cancer (see
Section VI.A.1). However, very little is known about the
underlying regulation of this expression or activity, al-
though circulating estrogen concentration most likely
plays a role.
The promoter region and 5 upstream regulatory ele-
ments of the STS gene were first characterized in human
placenta (51); however, this promoter was noted to lack
basal activity, suggesting additional regulatory elements.
Subsequently, tissue-specific STS isozymes with different
kinetic parameters for DHEAS and E1S were discovered
(52–54). Zaichuk et al (52) characterized the 5 heteroge-
neity of the human STS gene inMCF7 cells. The STS gene
exhibits alternative splicing and promoter usage, which is
likely to be the basis for tissue-specific regulation. 5-
Rapid amplification of cDNA ends analysis has identified
eight splice variants used in STS transcription based on the
Figure 2.
Figure 2. SUMF1 and FGE. SUMF1 encodes for the enzyme FGE, which catalyzes the conversion
of cysteine to FGly found at the FGE-recognition site LCTPSR on STS. This reaction results in
increased steroid desulfation by elevated STS activity.
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first six exons. First reported was exon 1a from placenta,
which utilizes DHEAS as the major steroid produced by
fetal adrenal glands and the main source of active estro-
gens (55). All splice variants encode the same active pro-
tein and all, except exon 1d which is found only in pe-
ripheral mononuclear leukocytes, vary in length with
multiple transcription start sites with tissues generally ex-
pressing one or more of these variants. Heterogeneity in
signal peptide sequences is thought to facilitate folding
and localization of proteins to the correct intracellular
compartment (19, 46).
STS mRNA and activity are higher in many cancerous
tissues compared to normal, implying an important role in
hormone-dependent tumor growth (see Section VI). Al-
though ubiquitously expressed, the regulation of STS ex-
pression does appear to be tissue specific and is subjected
to various feedback mechanisms, such as that shown by
the positive correlation between STS and estrogen recep-
tor (ER) isotypes mRNA (52). In MCF7 cells, STS tran-
scription may be up-regulated by E2 via direct binding to
ERandactivationof estrogen response elements in theSTS
promoter regions. Furthermore, MCF7 cells treated with
antiestrogen ICI182780 displayed reduced basal and E2-
stimulated expression of all STS mRNA. E2 also induced
ER degradation in an autoregulatory feedback loop,
whereas pretreatmentwithproteasomal inhibitorMG132
prevented this. Exposure to E2 and MG132 resulted in
STS mRNA increase, whereasMG132 alone reduced STS
mRNA (52, 56). Thus, to control estrogenic tissue, STS
expression may be regulated by local estrogen concentra-
tions in an ER-dependent manner. However, as yet, this
pathway for STS regulation has not been demonstrated in
other cell lines, suggesting that it may be unique toMCF7
cells.
In addition to thepotential for estrogens to regulate STS
activity, the proinflammatory cytokines IL-6 and TNF
alter STS enzyme kinetics. MCF7 cells increase STS activ-
ity in response to IL-6 andTNFwithout alteration in STS
mRNAlevels (57, 58), a trait alsonoted inother cancer cell
lines (59). This suggests that post-translational modifica-
tions, possibly via STS glycosylation, are involved in reg-
ulating STS activity (17, 60, 61). However, it cannot be
currently ruled out that these cytokines alter membrane
permeability and therefore increase substrate availability,
which is then perceived as an increase in STS activity (62).
Regulation of STS by inflammatory mediators is of in-
terest, considering that sex steroids have a role in immune
functions, inflammatory processes (63, 64), and cancer,
where STS activity is frequently dysregulated and often
associated with inflammation (65). Both epidemiological
and immunological evidence implies that steroids can in-
fluence the pathogenesis of many chronic inflammatory
diseases (66). For example, in the vascular smoothmuscle
cells of atherosclerosis patients, STS was found to be
higher in females with mild atherosclerotic changes com-
pared to severe disease and male aortas. Additionally, the
counterpart of STS, estrogen sulfotransferase (SULT1E1),
was lower in females with severe disease (67), suggesting
the importance of the STS/SULT ratio in the local regula-
tion of estrogen formation in inflammatory disease states.
How this alteration in ratio affects disease inflammatory
progression remains ill-defined.
III. Steroid Sulfotransferases and
PAPS Synthases
A. Molecular overview and functionality
Endocrine sulfation pathways include sulfate uptake,
conversion of this inert anion to active sulfate in the form
of 3-phospho-adenosine-5-phosphosulfate (PAPS), and
transfer to steroid hydroxyl groups by sulfotransferases.
Sulfate is anobligatenutrient providedmainlyby foodand
drinking water, taken up from the gut by several sulfate
transporters of the solute-linked carrier (SLC) 13 and 26
gene families (68), and to aminor extent also by oxidation
of cysteine and methionine amino acids (69).
Enzymatic sulfate activation by PAPS synthase is es-
sential due to the inert nature of the sulfate ion; this acti-
vation occurs via consecutive enzymatic steps (Figure 3)
(70, 71). First, the AMP moiety of ATP is transferred to
sulfate catalyzed by the ATP sulfurylase activity of PAPS
synthase, yielding adenosine-5-phosphosulfate (APS).
Formation of this unusual phospho-sulfo-bond is highly
endergonic, so that subsequent cleavage of the release py-
rophosphate by ubiquitous pyrophosphatases and an ad-
ditional phosphorylation step are needed to draw the re-
action to completion. This phosphorylation of APS at its
ribose 3-hydroxyl group is carried out by the APS kinase
domain of PAPS synthase, resulting in 3-phospho-APS
(PAPS) (70). PAPS is the universal sulfate donor required
by all human sulfotransferases, and in humans and most
vertebrates it is exclusively produced by two bifunctional
PAPS synthases, PAPSS1 and PAPSS2 (72). Active sulfate
in the form of PAPS is used by sulfotransferases for sul-
fation of a multitude of hydroxyl and amino groups in a
diverse array of biomolecules, including steroids. The by-
product of this reaction, the bis-phospho-nucleotide 3-
phospho-adenosine-5-phosphate (PAP), is then degraded
by dedicated phosphatases (73, 74) (see Section III. C.).
Sulfotransferases are a large gene family traditionally
classified into membrane-bound, Golgi-residing enzymes
(75) and soluble, cytoplasmic sulfotransferases (76). Gol-
gi-residing sulfotransferases are responsible for sulfation
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of proteins, carbohydrates, and proteoglycans, whereas
cytoplasmic sulfotransferases modify mainly hydropho-
bic, low-molecular-weight substances such as phenols, xe-
nobiotics, and steroids. Recent research has provided an
increasing number of structural studies on cytosolic sul-
fotransferases, but also with Golgi sulfotransferases, eg,
the carbohydrate 2-O (77) and 3-O-sulfotransferase (78)
aswell as the first structure of a protein sulfotransferase—
the human TPST2 protein (79). Sequence conservation is
rather low between these different sulfotransferases, but
their fold and catalytic features including binding of the
PAPS cofactor are highly conserved. Central to all sulfo-
transferases is an /-motif consisting of a five-stranded
parallel -sheet; the 5 phosphosulfate loop-loop consist-
ing of a strand-loop-helix structure, which is involved in
binding the phosphosulfate moiety of the PAPS cofactor;
and an additional conserved-helix (80). Ensembl lists 62
sulfotransferase genes within the human genome (includ-
ing four pseudogenes) (81) (Ensembl release 76). Sixteen
of these represent cytoplasmic sulfotransferases, and five
of these are associated with steroid sulfation: SULT1A1,
SULT1E1, SULT2A1, as well as the two isoforms of the
SULT2B1 gene, SULT2B1a and SULT2B1b (Table 2)
(82).
Physiological studies on SULTs are hampered because
sulfotransferase repertoires are different between mouse
and man; thus, findings in mice cannot always directly be
Figure 3.
Figure 3. Human sulfation pathways are complex. The various parts of human sulfation pathways are schematically depicted. Several sulfate
transporters are responsible for cellular sulfate uptake (reviewed in Refs. 59 and 62), followed by the two-step enzymatic sulfate activation by
bifunctional PAPS synthases. PAPS is then either used directly by cytoplasmic and nuclear sulfotransferases or shuttled to the Golgi apparatus to
serve a multitude of Golgi-residing carbohydrate and protein sulfotransferases. In contrast to the nonsulfated biomolecules, sulfated xenobiotics or
steroids need designated organic anion transporters to enter or exit cells. Many different sulfatases exist to cleave sulfate esters again. The
otherwise toxic, sulfation by-product PAP needs to be removed by dedicated phosphatases (reviewed in Ref. 65). In this review, we focus on
sulfate activation, steroid sulfation, and desulfation as well as the transport of steroid sulfates via organic anion transporters. For all other steps,
the reader may refer to the reviews given above.
Table 2. Sulfotransferases and Their Steroid Substrate
Steroid SULT Km Values Refs.
DHEA SULT2A1 0.8–3.7 M 102, 120, 313, 414–418
SULT1E1 0.2 M 419
Androsterone SULT2A1 2.1 M 415
Pregnenolone SULT2A1 1.94.9 M 102, 313
SULT2B1a 4.4 M 102
E1 SULT1E1 0.2 M 419
E2 SULT1E1 4–300 nM 118, 121, 418–420
SULT1A1 240 nM 421
Cholesterol SULT2B1b 1.2 M 102
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translated to human physiology. Only 46 of the above-
mentioned62human sulfotransferases have adirect coun-
terpart in mice. Although SULT3 genes are expressed in
rodents, there is merely a nonfunctional SULT3 pseu-
dogene in humans. Within mammals, a SULT5A1 gene
can be found in rodents, but has been lost from all other
mammalian genomes (81) [Ensembl release 76; ENS-
MUSG00000000739]. Furthermore, a single copy of the
SULT2A1gene in humans contrastswith a large gene clus-
ter inmice (SULT2A1-SULT2A7), possibly explaining the
absence of a suitable SULT2A1 knockout model. On the
other hand, whereas there is only one SULT1A gene in
mice, the SULT1A gene family forms a genomic cluster in
humans at chromosome 16p11.2, with one gene duplica-
tion into 1A1 and 1A3 type proteins within simians about
42 million years ago and two further gene duplications in
hominines (about 8million years ago) resulting in the four
1A genes found in chimpanzees and humans (81) [En-
sembl release 76; ENSG00000196502]. SULT1A3 and
SULT1A4 encode identical proteins, and a unique gluta-
mate residue at position 146 drives these sulfotransferases
toward sulfation of catecholamines (83). Interestingly,
specification at the human 16p11.2 locus does not stop
here because for the SULT1A1 gene, interindividual dif-
ferences in gene copy number have been described, with
some individuals carrying up to five SULT1A1gene copies
correlating with elevated SULT1A1 activity (84).
Cytosolic SULTs generally show broad substrate spec-
ificity. Taking the metabolic capacity of the microbiota
additionally into account (85), virtually unlimited num-
bers of substrates may be sulfated. Traditionally, certain
sulfotransferases were named according to their presum-
ably preferred substrate, eg, estrogen sulfotransferase
(SULT1E1) and DHEA sulfotransferase (SULT2A1). In
light of the greatly overlapping affinities of different ste-
roids to different SULTs (Ref. 86 and Table 2), the most
likely sulfotransferase for E2 sulfation may still be
SULT1E1 (because SULT1A1 and SULT1A3 have much
lower affinities for estrogens, withmaximal activity in the
micromolar range).DHEA, however,may also be sulfated
by SULT1E1 or SULT2Bs, in addition to SULT2A1. On
the other hand, SULT2A1 sulfates several other steroids as
well as many xenobiotics. A comprehensive study com-
pared ligand-bindingprofiles for eight humanSULTs (87);
out of SULT1C-1 to -3, SULT1B1, SULT1A1, SULT1A3,
SULT2A1, and SULT1E1, E1 only bound to SULT1E1;
2-hydroxyestradiol only bound to SULT1C3, 4A1, 2A1,
and 1E1; DHEAS only bound to SULT2A1 and 1E1; and
the bile acid lithocholic acid only bound to SULT2A1 and
1E1.
The broad substrate specificity of the sulfotransferase
enzymesmaybe linked to three highly flexible loops flank-
ing the catalytic binding site that can adapt to various
ligands. These loops are the least conserved parts between
different sulfotransferases. One of them, Asn226-Gln244
in SULT2A1, is referred to as a “cap that closes in,” once
the PAPS cofactor is bound with Arg247 (conserved in all
SULTs)making direct contact to this nucleotide (88). This
gating mechanism confers substrate specificity (89), and
the equilibrium between open and closed conformations
may restrict access to the catalytic core for larger ligands,
whereas sulfation of smaller substrates is unaffected (88).
Active site plasticity may be a general feature of SULT
enzymes (90), and it has two direct consequences for the
interaction of SULT2A1 with steroid molecules. First, the
steroidmoleculemaybind inanonproductivewaycausing
substrate inhibition (91). Second, for some pseudosym-
metric steroids with two hydroxyl groups, the substrate
plasticity of SULTs allows sulfation also at other hydroxyl
groups than thenormally targeted3-hydroxyl groupof the
steroid A-ring. Interestingly, this change in stereoselectiv-
ity may happen in SULT2A1 upon allosteric binding of
certain drugs, eg, celecoxib, a cyclooxygenase-2 inhibitor
(92). Furthermore, bis-sulfated steroids may be created in
this way that represent poorer substrates for STS (93).
Given this substrate promiscuity of sulfotransferases, it is
essential to understand the regulation of tissue-specific
expression of the different SULT genes.
B. Tissue and cellular distribution
Sulfotransferase enzymes are broadly expressed in the
human body. Tissues that putatively have the highest sul-
fation activities are those that are affectedmost severely by
loss of the ubiquitously expressed 3,5-bisphosphate nu-
cleotidase (BPNT1) phosphatase, the enzyme that re-
moves cytoplasmicPAP, theotherwise toxic by-product of
sulfation, by degrading it into AMP and phosphate. In the
BPNT1 knockout mouse model, the tissues mainly af-
fected are hepatocytes as well as enterocytes of the early
small intestine and proximal tubule epithelial cells of the
kidney (94); however, it should be noted that adrenal ste-
roid synthesis in these knockout animals was not
investigated.
The expression of five sulfotransferases (SULT1A1,
SULT1A3, SULT1B1, SULT1E1, and SULT2A1) was re-
cently compared in four human tissues (liver, intestine,
kidney, and lung) by quantitative Western blotting (95).
The highest concentrations of sulfotransferases were
found in liver and intestine consistentwith the above,with
SULT1A1/SULT2A1 and SULT1B1/SULT1A3A1 the
most/second most prevailing SULTs in these tissues (95).
SULT1E1hasbeen identified as themajor sulfotransferase
in lung tissue, whereas expression is at lower levels in liver
and intestine andnonexistent in thekidney (95). SULT1E1
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may play amore important role during fetal development,
being highly expressed in fetal liver and lung (96, 97).
SULT1A1 and SULT1B1 were found in all four tissues
tested; SULT1A3was found in kidney, lung, and intestine,
but not in liver (95). Therefore, SULT2A1may exclusively
carry out hepatic sulfation of orally administered and ex-
ternally absorbed DHEA.
Within the human adrenal cortex, SULT2A1 is specif-
ically expressed in the zona reticularis (98, 99), and hence
this sulfotransferase is responsible for themassiveDHEAS
production in this tissue. Strong adrenal expression of
SULT2A1, compared to SULT2B1a and SULT2B1b, was
also reported by Javitt et al (100). Thus, one may regard
SULT2A1as agenewithdual functionality, detoxification
of xenobiotics in the liver andmaintaining steroid homeo-
stasis in the adrenal; its secondary adrenal function may
have been gained only during primate evolution (101).
All of these sulfotransferases need to be provided with
active sulfate in the form of PAPS, and hence the coex-
pression of at least one of the two PAPS synthase genes is
crucial for their functionality.ThePAPSS1gene is thought
to be expressed ubiquitously (82, 102), whereas PAPSS2
seems to be expressed in a tissue-specific manner, with
particularly high expression in the adrenal glands, colon,
lung, and liver. PAPSS2 gene expression seems to bemore
dynamically regulated (103–105).
C. Regulation of sulfotransferases and PAPS
synthase activity
Sulfotransferase genes arepart of thephase-II-biotrans-
formation machinery targeting drugs and xenobiotics,
and as such their transcriptional regulation (mainly of
SULT1A1 and SULT2A1) is highly complex, involving
regulationby several nuclear receptors like thepregnaneX
receptor (PXR) and the constitutive androstane receptor
(CAR) (106). These receptors are activated by xeno- and
endobiotics, and they also regulate the expression ofmany
other detoxification genes like cytochromes P450 and uri-
dine 5-diphospho-glucuronosyltransferases (107). What
makes sulfotransferases special in this regard is that the
ligands activating those nuclear receptors are substrates
for sulfation, and this sulfation usually decreases ligand
binding to the respective nuclear receptor, representing a
crucial feedback regulation loop. Noteworthy, sulfation
may convert some nuclear receptor ligands into effective
receptor antagonists. This phenomenon, well described
for oxysterols and their involvement in the regulation of
bile acid detoxification andultimately lipidmetabolism, is
further described in Section V.B.2.
The transcriptional regulation of SULT gene expres-
sion by nuclear receptors may even result in cross-talk
between different steroid hormones. In this regard,
induction of the cholesterol-preferring sulfotransferase
SULT2B1b by the vitamin D receptor was recently shown
(108). Furthermore, glucocorticoids may antagonize es-
trogen function by glucocorticoid receptor-mediated
transcriptional up-regulation of estrogen sulfotrans-
ferase SULT1E1 (109, 110), resulting in inactivating
sulfation of E2.
Many studies on transcriptional regulation of SULTs
have focused on the SULT2A1 gene (111, 112). In fact, in
amousemodel for hyposulfatemiadue todisruptionof the
NaS1 sodium sulfate cotransporter, SULT2A1 is the only
sulfotransferase that shows significant changes in expres-
sion (113). Interestingly, transcriptional coregulation of
the genes for SULT2A1 and the producer of active sulfate,
PAPSS2, has been shown in some cases (103, 104). The
murine Sult2a1 gene may also be coregulated with the
DHEAS efflux transporterMrp4 through the nuclear re-
ceptor CAR,withMrp4 knockdown reducing Sult2a1 ex-
pression and CAR activation increasing both Sult2a1 and
Mrp4 (114).
Most studiesonxenobiotic-induced transcriptional up-
regulation of SULTs focus on hepatic detoxification path-
ways, mainly in rodent models. In human adrenal cells,
SULT2A1 gene expression is increased upon stimulation
by CRH or ACTH (115) and regulated by the nuclear
receptor steroidogenic factor 1, the transcription factor
GATA-6 (116), and ER (98). Although binding of all
these transcription factors to the human SULT2A1 pro-
moter has clearly been demonstrated, this still does not
explain the striking specificity of SULT2A1 expression
within the human zona reticularis or the remarkable
changes in SULT2A1 expression directly after birth, dur-
ing adrenarche, and in human aging.
On the protein level, SULTs are subject to substrate
inhibition (eg, DHEA binding to SULT2A1). SULTs are
usually exposed to different substrates at the same time.
Some xenobiotics are able to bind to the mostly hydro-
phobic ligand binding sites of SULTs, thereby blocking
enzyme activity. This mechanism may explain the hor-
mone-like, estrogenic action of endocrine disruptors that
otherwise do not bind and activate the ER (117). Estrogen
action can be enhanced by the potent inhibition of
SULT1E1, resulting in reduced estrogen inactivation by
sulfation, mediated by hydroxylated metabolites of poly-
halogenated aromatic hydrocarbons (118). As an exam-
ple, tetrabromobisphenol A, a commonly used flame re-
tardant,mimicsE2binding toSULT1E1,makinguseof the
versatile substrate binding pocket and inhibiting the ac-
tivity of the enzyme (119). These findings highlight the
potential of xenobiotics to cause endocrine disruption by
interfering with steroid sulfation without the need to bind
to hormone receptors directly.
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It is well established that product inhibition of SULTs
by the side-product of sulfation reactions, PAP, can occur
via the formation of a dead-end enzyme-PAP-substrate
complex (120). Because PAP binds to SULT1E1 with an
affinity (Kd) of 30 nM (121), this inhibition may be phys-
iologically relevant and can be counteracted by the above-
mentioned nucleotide phosphatases that specifically de-
grade PAP to AMP and phosphate: BPNT1 phosphatase
and its Golgi-resident paralog (Golgi-resident PAP phos-
phatase [gPAPP]) (74). Loss of the BPNT1 gene leads to
impaired protein synthesis resulting in impaired hepatic
function and low serum albumin levels in mice (73).
On the other hand, SULT activity is generally regulated
by the availability of active sulfate in the form of PAPS
(122). PAPS tissue concentrations tend to be in the lower
micromolar range (4–80nmol/g tissue), yet sulfation rates
can be relatively high, resulting in depletion of the entire
hepatic PAPS pool in less than 1 minute (123), requiring
rapid and constant dynamic delivery of PAPS. Biosynthe-
sis of PAPS, on the other hand, is energetically very costly
(the three phospho-phospho-bonds that need to be
cleaved are equivalent tomore than 90 kJ/mol), and hence
this pathway and the PAPS synthases involved are subject
to tight regulation on various levels, including regulated
nucleo-cytoplasmic shuttling (124), dimerization (125),
and stabilization by ligand binding (70).
IV. Cellular Influx and Efflux of
Sulfated Steroids
Hydrophilic sulfated steroids require active transmem-
brane transport for cellular uptake. Because these endo-
biotics are generally organic anions, cellular influx and
efflux are regulatedbynumerous transporter proteins that
belong to two major superfamilies: solute carrier (SLC)
transporters, and ATP-binding cassette (ABC) transport-
ers. Evidence suggests that most transporters are bidirec-
tional; however, ABC transporters generally mediate ef-
flux, and SLC transporters mediate influx (126). Two of
the 52 gene families within the SLC transporters, the
SLCO and the SLC22A superfamilies, contain transport-
ers involved in sulfated steroids transport. The SLCO su-
perfamily contains OATPs (127), and the SLC22A super-
family contains the organic cation transporters and the
organic anion transporters (OATs) (128). TheOATPs are
the primary transporters for sulfated steroid influx, with
each OATP possessing distinct uptake kinetics and sub-
strate specificity for different conjugated steroids (Table
3). However, it should be noted that some OATs (OAT1,
OAT3, OAT4, and OAT5) can transport sulfated steroids,
particularly E1S in human placenta (129) and kidney (130).
Conversely, cellular efflux of conjugated steroids oc-
curs through the ABC transporters multidrug-resistant
protein (MRP) and in certain instances through breast
cancer-resistant protein (BCRP) (131). Usually associated
with cancer drug resistance, ABC transporters are trans-
porting polypeptides that utilize ATP-binding and hydro-
lysis to transport various substrates across membranes.
Thirteen MRPs have so far been identified within the hu-
man genome, although MRP1 (also known as ABCC1)
and MRP4 are considered most efficient in mediating ef-
flux of sulfated steroids.
Taken together, the relative extent ofOATP,MRP, and
BCRP tissue expression directly relates to total steroid in-
tracellular concentration, and therefore these transport
mechanisms are likely to play key roles in regulating ste-
roid action (Figure 4).
A. OATP-regulated influx
There are numerous OATPs expressed in almost all
epithelia throughout the human body. In addition to con-
jugated steroids, they are involved in the cellular uptake of
a large range of substrates, including bile acids and xeno-
biotics. The mechanism of OATP-mediated transport re-
mains controversial, although all agree that transport is
ATP- and sodium-independent (126). However, what
drives uptake is still ill-defined. OATPs can transport bi-
directionally, and evidence suggests that they may act as
electroneutral exchangers. For example, someOATPs ex-
change substrates for intracellular bicarbonate (132), glu-
tathione (133), or glutathione conjugates (134).However,
transport mechanisms may differ with different OATPs
because glutathione does not mediate OATP1B1 and
OATP1B3 uptake (135). Furthermore, although acidic
pH levels (pH 5.5–6.5) generally elevate OATP2B1-me-
diated transport (136–139), this is not the case with re-
gard to E1S transported by OATP1B1 and OATP1B3
(135). Recent evidence suggests that these two transport-
ers are altered in different ways by both cell membrane
potential and local pH conditions (140).
B. MRP-regulated efflux
The ABC transporter MRP1 was first identified in
H69AR cells, a human small cell lung cancer cell line that
exhibits resistance to a broad range of natural product-
type drugs (141). Along with its role in drug resistance,
MRP1 also facilitates efflux of antioxidant glutathione
and the proinflammatory leukotriene C4 (142) as well as
E1S (143) and DHEAS (144), and is expressed in a range
of cancerous tissues including hormone-dependent breast
(145), prostate (146), and colorectal cancer (147). Trans-
port of E1S and DHEAS is distinguished by a dependence
on glutathione (148, 149), but the physicochemical prop-
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erties that determine whether or not sulfated steroid re-
quires glutathione for MRP1-mediated efflux remains
unresolved.
However, other MRPs should not be overlooked with
regard sulfated-steroid transport. Along with bile acids,
MRP8 facilitates the efflux of E217-glucuronide and E1S
(150, 151), and it has also been shown to transport
DHEAS in the caninekidney cell lineMDCK(152).MRP4
has also shown high affinity transport (at 2–10 M) of
DHEAS (149) and therefore may be involved in the reg-
ulation of adrenal DHEAS secretion. Intriguingly, Mor-
gan et al (153) demonstrated that MRP4 knockout mice
have decreased plasma T concentrations, a process re-
ported to be caused by impaired cAMP-response element-
binding protein in Leydig cells. Although these authors
measured circulating Androstenedione concentrations,
they do not report on circulating DHEAS concentrations
in these animals, an experiment that may demonstrate the
importance of this MRP4 in adrenal DHEAS secretion.
C. Estrone sulfate influx and efflux
MostOATP/MRP transport studies have utilized E1S be-
cause it represents amajor substrate formany transport pro-
teins (Table 3). Because estrogens can drivemany hormone-
dependent cancers, it is not surprising to find that most
studies on E1S transport are oncologically focused, and little
isknownabout the importanceofOATP-mediateduptake in
normalphysiology.However, studieshave shownthatmany
cancerous tissues and cell lines have altered OATP expres-
sion compared to healthy tissue. For example, the normally
liver-exclusive OATP1B3 is also expressed in gastric, colon,
pancreatic, prostate, and breast cancers (154–157).
Structural investigations of OATP proteins and E1S
transport are still at an early stage. Transmembrane do-
Figure 4.
Figure 4. Sulfated steroids are shuttled across the cell membrane by various OATPs. Different OATPs have differing affinities for different steroids.
Once intracellular, steroids can be desulfated by STS, and then resulfated by SULTs. The expression ratio between these competing pathways will,
most likely, define ultimate sulfation/desulfation outcome. Sulfated steroids can be removed from the cell via MRP1 and MRP4. Nonsulfated
steroids act intracellularly, or, because they are lipid soluble, they will diffuse across the cell membrane and potentially act in a paracrine fashion.
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mains (TMs), essential structural features of membrane
proteins critically involved in the proper function of other
transporters such as OATs, confer substrate specificity
across the OATP family. Thus, it has been shown that
TM8 and TM9 in OATP1B1 are critical for its substrate
recognition and E1S transport (158). More recently, phy-
logenetic analysis of OATP sequences has revealed that
TM2 is also among the TMs that have high amino acid
identities within different family members (159). Subse-
quently, Asp70, Phe73, Glu74, and Gly76 were found to
be essential for E1S uptake by OATP1B1 (159), although
whether this is true across other OATPs remains to be
determined.
Initial studies pinpointed hepatic OATP1B1 as the ma-
jor E1S transporter (160), and recent evidence suggests
that OATP1B1 is overexpressed in hormone-dependent
breast cancer cell lines such as MCF-7 compared to non-
cancerous epithelial MCF-10A cells (161). Following
these early studies, evidence came that OATP1B1 (162,
163), OATP1B3 (162, 164, 165), OATP2B1 (162, 166),
and OATP1A2 (167) also transport E1S. The expression
of these “sulfated-hormone transporters” (OATP1B1,
OATP1B3,OATP2B1, andOATP1A2) is low, if not com-
pletely absent, in many normal endocrine tissues (166,
168) but is elevated in hormone-dependent cancers arising
in these same tissues (168). Indeed, with regard to
OATP1B3, there is now strong evidence suggesting that
this transport polypeptide becomes a specific cancer-vari-
ant isoform localized to colon, lung, andpancreatic cancer
(169, 170). This suggests that OATP overexpression and
subsequent increased sulfated-hormone cellular influx,
along with other substrates, is important in cancer pro-
gression, and therefore theseproteins represent novel ther-
apeutic targets against estrogen-driven carcinomas. In-
deed, inhibiting E1S uptake by using organic anions such
as bromosulfophthalein, which competes as a substrate
for all OATPs, blocks E1SMCF-7 cell proliferation (171).
Some evidence suggests that it is primarily OATP1B3 that
transports E1S in breast cancer (156), making it an attrac-
tive specific target for inhibitor studies. However, it is
evident that manyOATPs can transport E1S, and thus the
jury remains out on whether selectively targeting just one
OATP toblockE1S-uptake is a viable therapeutic strategy.
The kinetics of E1S uptake can be influenced by various
factors, notably local pH and solute conditions. For ex-
ample, E1S uptake by OATP1B3 is Na
 independent
(126). Intriguingly, OATP2B1-mediated uptake of E1S is
enhanced in the presence of progesterone (172, 173). This
finding is of special relevance for the formation of estro-
gens in tissues like placenta and mammary gland, which
depend on the uptake of precursor molecules for steroid
hormone synthesis like E1S and DHEAS, and provides an
indicationof the importance ofOATP transport in normal
physiology.
Table 3. OATPs Expression Patterns in Endocrine Tissue and Their Known Conjugated Steroid Substrates
Influx Transporter Expressed in Cell
Lines and Tissue (Ref.) Substrate Km Values, M Refs.
OATP1A2
Breast (145, 161, 167) DHEA-3-sulfate 7 173, 175
Prostate (179) E2-17-glucuronide 424
Placenta (422, 423) E1-3-sulfate 16 167, 173, 425
OATP1B1
Breast (161) DHEA-3-sulfate 22 154, 162, 173, 298
Prostate (168) E2-17-glucuronide 4–24 162, 164, 298
Ovary (426) E1-3-sulfate 0.09–45 162, 163, 173, 298
OATP1B3
Breast (156, 161) DHEA-3-sulfate 162, 164, 165, 173, 298
Prostate (157, 168) E2-17-glucuronide 5–25 162, 164, 298
Placenta (423) E1-3-sulfate 137, 165, 171, 298
Ovary (426)
Intestine (155, 168)
OATP1C1
Testes (166) E2-17-glucuronide 166
Placenta (427) E1-3-sulfate 166
T4 sulfate 428
OATP2B1
Breast (161, 166, 429) DHEA-3-sulfate 9 166
Placenta (181, 430) E1-3-sulfate 1.56–21 137, 138, 163, 166, 172, 173
Intestine (138) Pregnenolone sulfate 172
OATP3A1
Breast (161) E2-17-glucuronide 160
E1-3-sulfate 160
Only six of the 11 OATPs are included because the remaining OATPs have not shown sulfated steroid transport.
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With regard to efflux transport,MRP1 and BCRP both
influence total E1S uptake. By preloading Caco-2 cells
with tritium-labeled E1S and then inhibiting BCRP and
MRP1activity,Grandvuinet et al (174) demonstrated that
these efflux transporters are actively involved in intracel-
lular E1S availability, thus suggesting that the relative ex-
pression of OATP, MRP1, and BCRP will ultimately de-
termine intracellular estrogen concentrations. However,
definitive studies investigating the relative importance of
all these transporters in E1S uptake have not yet been
performed.
D. DHEAS influx and efflux
DHEAS transport was first demonstrated in Xenopus
laevis oocytes overexpressing the human OATP1A2
(175). Similar to most studies on E1S, research into
DHEAS transport is sparse and again mainly focuses on
uptake in cancerous cells. Obviously, interest has focused
on the prostate because it is known that prostate cancer
cells possess STS activity (176) to desulfate DHEAS, fol-
lowed by downstream conversion of DHEA to andro-
stenedione (177) resulting in androgen receptor (AR) ac-
tivation. More pertinently, OATPs involved in DHEAS
influx are elevated in human castration-resistant meta-
static prostate cancer (178). Indeed, under androgen de-
privation, LNCaP cells elevateOATP1A2 expression, and
knockdown of this transporter significantly attenuates
DHEAS-driven proliferation (179).
In the placenta, DHEAS uptake seems to be regulated
by OATP2B1 transport (180). Placental DHEAS uptake
correlates with OATP2B1 and BCRP expression, suggest-
ing an interactionof these twoproteins in regulating trans-
port of DHEAS (181).
E. Genetic variation and regulation of OATP expression
The genetic variation in various OATPs (OATP1B3,
OATP1B1, OATP1A2) has also been shown to affect
overall steroid uptake in a variety of cell lines (182). For
example, transfectionof SLCO1B1 single nucleotide poly-
peptide rs4149056 (37041TC) into HEK293 cells re-
sults in lower cell surface expression and thus lower E1S
uptake compared to wild-type transfections (183). This
was also seenwith SLCO2B1SNP rs2306168 (1457CT)
transfection, where E1S uptake was less than half that of
thewild-type variant (184). Further studies are required to
determine whether these SNPs are important in sulfated
steroid uptake in cancerous cells.
However, support on the importance of genetic varia-
tion in OATPs and DHEAS uptake comes from various
clinical studies examining these transporters and prostate
cancer outcomes. For example, in a cohort of 538 patients
suffering metastatic hormone-sensitive prostate cancer,
men with each of three OATP2B1 alleles (rs12422149
[935GA; Arg312Gln], rs1789693, and rs1077858) had
a shorter median time to progression of 10, 7, and 12
months, respectively; and this effect was additive (185).
Patients with multiple “at-risk” OATP2B1 variants (in-
cluding OATP2B1 allele rs12422149 935G, which has a
high-transport efficiency for DHEAS), who also had the
high T transportOATP1B3 SNPs, had the shortest time to
progression. These data have been supported by a study
examining532 Japanesemen,wherehomozygosity for the
OATP2B1 rs12422149 935G variant was associatedwith
shorter median time to progression (186).
Little is knownregardingOATPregulation, andwewill
only focus on theOATPs with substrate affinity with con-
jugated steroids. Generally, OATP expression is con-
trolled by transcriptional regulation (126) and is most
likely tissue specific. OATP1B1 expression is dependent
on Hepatic Nuclear Factor 1 (187, 188) and may also
involve Signal Transducer and Activator of Transcription
5 (189), Interferon- (190), and IL-1 (191). In contrast,
it is bile acids that can up-regulate OATP1A2 expression
in intestinal and liver tissue (192), although inbreast tissue
OATP1A2 regulation is significantly associated with
PXR expression (193). Meyer zu Schwabedissen et
al(167) have also demonstrated that OATP1A2 is up-
regulated in malignant breast tissue, with this elevation
directly related to E1S uptake. Furthermore, OATP1A2
expression is regulated by activation of the nuclear re-
ceptor PXR, whose primary function is to sense foreign
toxins and in response up-regulate OATPs for detoxi-
fication and clearance purposes.
V. Disease-Causing Mutations Affecting
Steroid Sulfation and Desulfation
A. Pathogenic mutations in steroid sulfatases
and SUMF1
1. X-linked ichthyosis (STS deficiency)
Mutations or deletions of the STS gene result in a skin
condition called “X-linked ichthyosis” (XLI), which in
approximately 80% of cases is due to complete deletions
of the STS gene (31, 194, 195). XLI is also termed STS
deficiency and represents one of the common inherited
metabolic disorders, with 1:6000 live births and no geo-
graphical or ethnical variation (196–198).
Generally, ichthyosis refers to genetically and acquired
disorders of the skin characterized by abnormal keratini-
zation; the skin often resembles “fish scales,” explaining
theoriginof the term ichthyosis fromGreek ichthys, trans-
lated as fish. XLI was first recognized in the 1960s as a
distinct form of ichthyosis due to a distinct clinical ap-
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pearance and the mode of inheritance (196, 199). It is
characterized by large, dark-brown, and tightly adherent
scales found at most areas of the skin, but predominantly
symmetrically located on the trunk, the neck, and the ex-
tensor surfaces. The scalp is nearly always affected; how-
ever, plantar and palmar surfaces are spared. The scaling
starts a few months after birth, and generally tends to
improve during the summer months.
The underlying pathophysiology of the excessive scal-
ing/hyperkeratosis results from impaired cholesterol me-
tabolism. STS catalyzes the breakdown of cholesterol sul-
fate in the outer layers of the skin (stratum granulosum
and stratum corneum) (200). In patients with XLI, where
there is no STS activity, this breakdown is impeded and
cholesterol sulfate, which physiologically stabilizes cell
membranes and adds cohesion (201), accumulates in the
stratum corneum causing partial retention hyperkeratosis
with visible scaling (194, 200, 202).
Cryptorchidism has been reported in up to 20% of pa-
tientswithXLI (203–207).Because thepatients fromthese
reported case series were not genetically characterized, it
is unclear whether the testicular maldescent is a direct
consequenceof STSdeficiencyor secondary todeletionsof
adjacent genes to the STS locus. Indeed, complex syn-
dromes including XLI due to contiguous gene deletions
of the X chromosome are reported, including Conradi-
Hunermann syndrome (OMIM302960; limb shortening,
epiphyseal stippling, craniofacial defects, short stature)
and Rud syndrome (OMIM 308200; cryptorchidism,
retinitis pigmentosa, epilepsy, and mental retardation).
Lynch et al (208) reported anX-linked recessive pattern of
concomitant XLI with hypogonadism in one family with
five males affected. Although anosmia has not been re-
ported in this kindred, it seems likely that a contiguous
gene syndrome affected both the STS and KAL1 loci. Re-
cent investigations in a fully genetically characterized co-
hort ofXLI patients and genetic abnormalities confined to
the STS gene indicate that testicular maldescent is rare. Of
30 males with XLI, only one boy had unilateral cryp-
torchidism (unpublished data), which is within the range
of the general population risk inWestern countries (209).
An association between STS deficiency and testicular
cancer independent of testicular maldescent has been hy-
pothesized and reported in two patients with XLI (210);
however, this report is the only one published to date. The
very first clinical presentation of XLI may occur at birth
because efficient desulfation of DHEAS and consequent
conversion ofDHEA to estrogens is important for cervical
softening (211), which would be disrupted in STS defi-
ciency. Thus, women carrying children affected by XLI
have reported prolonged labor due to insufficient cervix
dilatation (cervical dystocia) (204, 212, 213)—a severe
and unexpected birth complication where perinatal death
has been reported (214). Prenatal diagnosis of STS defi-
ciency is possible because maternal estrogen excretion is
decreased, and hence characteristically low estriol is
found. GC-MS analysis of maternal urine can help to dis-
tinguish fetal STS deficiency from other conditions asso-
ciated with low estriol, such as aromatase deficiency or
congenital adrenal hyperplasia due to P450 oxidoreduc-
tase deficiency, because sex steroid precursor metabolite
excretion inmaternal urineduring apregnancy affectedby
XLI is normal (215–217).
Androgen metabolism has been studied in several co-
horts of male XLI patients (218–222). Interestingly, in-
creased serum DHEAS was not consistently found in
XLI/STS-deficiency patients. Lykkesfeldt et al (221) in-
vestigated 20 adult males with XLI and found decreased
downstream androgens with a trend toward higher serum
DHEAS and lower serum androstenedione levels. An in
vivo study in healthy young men investigating DHEA-
DHEAS interconversion suggests that DHEA sulfation is
the predominant direction, whereas desulfation by STS
does not seem to play a role in normal adult physiology,
with no increase in circulating levels of DHEA or sex ste-
roids after iv DHEAS administration (223). This is con-
firmed for adult males from our cohort of 30 mixed adult
and pediatric patients with STS deficiency and age-
matched controls; however, the ratio of serum DHEA/
DHEAS, reflecting in vivo STS activity, is increased in the
prepubertal healthy boys, suggesting that STS is active
before puberty, contributing toward peripheral androgen
activation. In addition, the global 5-reductase activity,
determined by urinary steroid profiling, is increased in
STS-deficient males, indicative of a compensatory mech-
anism counteracting a relatively reduced rate of tissue-
specific androgen activation (unpublished data).
Although STS may not contribute to peripheral andro-
gen activation in healthymale adults, ample placental STS
activity during pregnancy substantially increases circulat-
ing DHEA and sex steroid levels; accordingly, increased
levels after iv DHEAS challenge have been described
(224).
2. Multiple sulfatase deficiency
Multiple sulfatase deficiency (MSD;OMIM272200) is
a rare and severe autosomal recessive disease that affects
the function of all sulfatase enzymes, leading to a rather
complex phenotype, which essentially incorporates the
features of each single known sulfatase deficiency. The
elucidation of the underlying pathology in patients with
MSD has led to the discovery of a unique post-transla-
tional event, which is shared by all human sulfatase en-
zymes: the activation of a cysteine residue to form an ac-
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tivated FGly at the active site of the sulfatase, which is
thought to attack and subsequently cleave the sulfatemoi-
ety off the substrate (28) (see Section II.A,1). In 2003, the
SUMF1 genewas discovered to encode the FGE, revealing
the molecular basis of MSD (40, 41). To date, there are
about 30 mutations of the SUMF1 gene reported in pa-
tients with MSD, and clear genotype-phenotype correla-
tions have been observed linked to the residual activity of
FGE (225), leading to manifestations with severe neona-
tal, late infantile, or rarer mild juvenile forms of MSD
(226, 227).
To further understand the pathology of SUMF1 defi-
ciency, various groups have identified eight other disor-
ders genetically and clinically linked to deficiencies of dis-
tinct human sulfatase enzymes. Six of them represent
lysosomal storage disorders, where the sulfatase enzyme
fails to exert its catabolic function such as the desulfation
of sulfated glycolipids (via arylsulfatase A), leading to
the accumulation of sulfatides and the progressive demy-
elinization observed in metachromatic leukodystrophy
(OMIM 250100); or the accumulation of GAGs, includ-
ing heparin sulfate, dermatan sulfate, keratin sulfate, and
chondroitin sulfate, as observed in the various types of
mucopolysaccharidosis (see Ref. 14 for excellent review
and Section V.B.1). Patients with MSD therefore show
severe neurodegeneration with mental retardation, hepa-
tosplenomegaly, short stature (resembling mucopolysac-
charidosis), combined with XLI-type skin and skeletal
changes as observed in chondrodysplasia punctata
(OMIM 302950) (227).
3. Autism and ADHD
Recent studies have shown an association of XLI with
behavioral disorders, including autism, attention deficit-
hyperactivity disorder (ADHD), and social communica-
tion deficits; however, in the affected subjects, large gene
deletions in the proximity of the STS locus have been
found that included theNLGN4 gene encodingneuroligin
4, a synaptic peptide that has been previously implicated
in X-linked autism and mental retardation (228). How-
ever, the STS gene in 384 patients with ADHD identified
two SNPs of the STS gene that were significantly associ-
ated with ADHD (229). The authors hypothesized that
disturbed neuronal DHEA-DHEASmetabolismmight re-
sult in altered neurotransmitter function contributing to
the observed behavioral abnormalities. This has been sup-
ported in STS knockout mice that develop attention dis-
orders consistent with ADHD (230), which can be allevi-
ated with the administration of DHEAS (231).
B. Pathogenic mutations in steroid sulfotransferases and
PAPS synthases
1. Bone and cartilage malformations
Inborn defects in various genes involved in sulfate up-
take, activation, and utilization have been linked to
developmental defects in cartilage and bone (232). Dimin-
ished sulfate uptake is caused by mutations in the dia-
strophic dysplasia sulfate transporter gene (SLC26A2)
and causes diastrophic dysplasia, achondrogenesis type
IB, atelosteogenesis type II, and a recessive form of mul-
tiple epiphyseal dysplasia (68).
A missense mutation in the gene encoding the sulfate-
activating enzyme PAPSS2 has been described as associ-
ated with a brachymorphic phenotype in mice (233), with
normal levels of GAGs that are, however, severely under-
sulfated (234). Human PAPSS2 mutations were first de-
scribed in the context of a severely affected consanguine-
ous Pakistani kindred (235, 236). Mutations in PAPSS2
can cause varying forms of bonemalformation in humans,
ranging from subclinical brachyolmia with only mild ra-
diological spinal changes (237), via overt brachyolmia
with dysplasia confined to the spine (15 reported cases so
far) or with additional minimal epimetaphyseal changes
only visible on x-ray (four cases), to overt spondyloepime-
taphyseal dysplasia with both vertebrae and long bones af-
fected (23 reported cases), as summarized recently (238).
Undersulfation of the GAG chondroitin sulfate may
also be caused by inactivating mutations of the chondroi-
tin 6-O-sulfotransferase gene, CHST3, resulting in severe
chondrodysplasia with progressive spinal involvement
(239) and congenital joint dislocations in humans (240). It
has been assumed previously that undersulfation ofGAGs
directly leads to changes in the biomechanical properties
of cartilage (105). However, more likely, morphogen sig-
naling involving hedgehog proteins, wingless-related pro-
teins, and fibroblast growth factors may be compromised
by changed chondroitin sulfate proteoglycans because all
of these growth factors interact with the extracellular
matrix (241).
Bone and cartilage malformation caused by sulfation
defects contrasts with bone and cartilage phenotypes due
to sulfatase defects. The sulfate group transferred to N-
acetylgalactosamine of chondroitin sulfate by CHST3 is
the same as that removed in the lysosomes by Gal-NAc-
6-sulfatase, the enzyme deficient in mucopolysaccharido-
sis type IV A (also known as Morquio syndrome; OMIM
253000). This highlights the importance of the correct
balance of sulfation and desulfation for bone and joint
development in humans.
Furthermore, the side-product of sulfation reactions,
the bis-phospho-nucleotide PAP, also has an impact on
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bone development. The phosphatase gene BPNT1, re-
sponsible for removal of cytoplasmic PAP, has a paralog
localized to the Golgi compartment, gPAPP (74), and this
gene has been associated with impairment of skeletal de-
velopment (242). More recently, patients were described
with homozygous missense (243) and homozygous trun-
cation mutations (244) in the gene encoding gPAPP. Af-
fected patients presented with short stature, joint disloca-
tions, brachydactyly, and cleft palate; these phenotypes
highlight the importance of fully functional sulfation
pathways in the development of skeletal elements and
joints.
2. Androgen excess, PCOS, and metabolic disease
Androgen excess is one of three hallmarks of polycystic
ovary syndrome (PCOS), the most common female endo-
crine disorder, affecting about 6–9% of women world-
wide (245). Furthermore, increased androgen levels are
associated with an adverse metabolic phenotype, increas-
ing the risk of insulin resistance, type 2 diabetes, obesity,
and cardiovascular disease (246). Many molecular causes
for androgen excess exist, with one possibility a failure in
the sulfationpathway that convertsDHEA toDHEAS, the
most abundant steroid in the human circulation. The ob-
vious candidate gene for such a disorder, SULT2A1, has
indeed been suggested to play a role in inherited androgen
excess in PCOS (247). Two recent studies looked at the
association of common genetic variants (minor allele fre-
quency  5%) in SULT2A1 and PAPSS2 with androgen
status without an obvious link between inherited genetic
variation and androgen excess (248, 249). However, rare
inactivating genetic variants of the PAPSS2 gene result in
apparent SULT2A1 deficiency associated with androgen
excess. This results from decreased conversion of DHEA
toDHEAS, consequently increasing theDHEApool avail-
able for downstream conversion to active androgens. The
resulting clinical androgen excess manifests with prema-
ture pubarche and early-onset PCOS, and of note, in both
families that were characterized in detail (237, 238, 250),
the heterozygous mothers carrying a major loss-of-func-
tion mutation on only one allele clinically presented with
PCOS. An association of circulating DHEAS levels with
common variants in the SULT2A1 and PAPSS2 genes has
been recently excluded in a population-based study (249).
Additionally, in a large PCOS cohort study (248), com-
mon SULT2A1 and PAPSS2 variants did not present as
risk alleles, although a common SULT2A1 allele variant
was associated with the serum DHEA/DHEAS ratio. Fur-
ther studies in PCOS cohorts including analysis of rarer
genetic variants are warranted.
Obesity is an important risk factor for PCOS because it
contributes further to the characteristically decreased in-
sulin sensitivity. Circulating estrogen levels may be in-
creased in obese patients due to enhanced aromatization
withinadipose tissues (251), andestrogens can regulate fat
mass distribution and glucosemetabolism. Thus, estrogen
action in obesity will be regulated by steroid sulfation be-
cause the estrogen sulfotransferase SULT1E1 is highly ex-
pressed in adipose tissue of male mice and induced by T in
female mice (252). Overexpression of SULT1E1 in a mu-
rine transgenicmodel results in reducedparametrial and sc
inguinal adiposemass and reducedadipocyte size, butnor-
mal retroperitoneal and brown adipose deposits (253);
SULT1E1 overexpression also prevents adipocyte differ-
entiation (254). In humans, however, SULT1E1 is a proa-
dipogenic factor (252). Its expression is reported to be low
in preadipocytes but increases upon differentiation toma-
ture adipocytes. Overexpression and knockdown of
SULT1E1 in human primary adipose-derived stem cells
promotes and inhibits differentiation, respectively (252).
If this holds true, SULT1E1 could represent a drugable
target, and adipose-specific SULT1E1 inhibitors could be
used to inhibit the turnover of adipocytes in obese
patients.
Steroid sulfation and desulfation pathways have both
been implicated in improving and/orworseningmetabolic
outcomes associated with obesity and type-2 diabetes. Es-
trogen and androgen concentrations have been implicated
in regulating energy and glucose homeostasis. For exam-
ple, mice lacking the aromatase enzyme become obese due
to attenuated physical activity and decreased lean body
mass (255), and ER-deficient mice exhibit reduced en-
ergy expenditure leading to an obese phenotype (256).
Estrogen deficiencies also result in impaired insulin sen-
sitivity inbotharomataseknockout (255) andERknock-
out mice (257). Conversely, estrogen administration im-
proves insulin sensitivity inhigh-fat-diet femalemice (258)
and ob/ob obese mice (259).
This evidence suggests an importance in both STS and
SULT1E1 activity in improving metabolic outcomes as-
sociated with obesity. Recent studies have examined the
effect of both enzymes on metabolic function in obesity
and diet-induced type 2 diabetes in mice. Hepatic
SULT1E1 expression, although normally low, is elevated
in type 2 diabetic mice, and loss of SULT1E1 improved
metabolic function in these same animals (260). Further-
more, SULT1E1 ablation increased energy expenditure
and insulin sensitivity and decreased hepatic gluconeo-
genesis and lipogenesis. This metabolic benefit resulted
from decreased estrogen sulfation, and therefore an in-
creased estrogenic activity in the liver; this effect was not
seen in ovariectomized mice (260). The same group then
developed a liver-specific STS knock-in mouse model and
demonstrated that increased hepatic active estrogen con-
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centrations are associated with an improved metabolic
function when compared to obese and type 2 diabetic an-
imals. Furthermore, they show that hepatic STS activity is
increased in mice given high-fat diets and in ob/ob obese
animals (261). This suggests that SULT1E1 and STS ac-
tivities are important in energy homeostasis and that up-
regulation of STS and thus an increased synthesis of es-
trogens may be a hepatic defensive response against the
metabolic syndrome.
Intracellular accumulation of lipids, inflammatory re-
sponses, and subsequent apoptosis are major pathogenic
events of metabolic disorders. Sulfated oxysterols also
play a role in lipid metabolism and obesity. For a long
time, it has been known that oxysterols, derivatives of
cholesterol, bind to LXR nuclear receptors and up-regu-
late hepatic de novo lipogenesis (262). LXR activation
also prevents bile acid toxicity (263). On the other hand,
LXR expression correlates with intrahepatic inflamma-
tion and fibrosis in patients with nonalcoholic fatty liver
disease (264). Recently, it became apparent that these nu-
clear receptor ligands, when sulfated, are not merely
blocked from binding, but are actively inhibiting nuclear
receptor signaling by yet unknown mechanisms (265),
putting steroid sulfotransferases into the context of energy
metabolism and regulation. Furthermore, sulfated sterol
signaling is not limited to LXR receptors, but it affects
several other members of the nuclear receptor family act-
ing then as metabolic sensors of intracellular lipid, bile
acids, and cholesterol levels: CAR, farnesoid X receptor,
peroxisomeproliferation activator receptors, and retinoid
X receptor (266). Sulfation of bile acids and oxysterols is
catalyzed exclusively by the SULT2A and SULT2B en-
zymes (100, 267). Hence, sulfated oxysterols may repre-
sent candidates for the development of novel therapeutic
approaches to nonalcoholic fatty liver disease (268), a
metabolic complication of obesity that continues to in-
crease in prevalence, now representing the second most
common cause of liver transplantation.
VI. Dysregulation of Steroid Sulfation
and Desulfation
A. Cancer
Steroid metabolism is significantly altered in many en-
docrine-related cancers (269). Evidence suggests that sul-
fationpathways are down-regulated,whereas STSactivity
increases in many tumors, thus favoring desulfation and
therefore downstream conversion of steroids into more
active metabolites (Figure 5).
1. Breast
Most breast cancers are initially estrogen responsive
and exhibit increased intratumoral estrogen concentra-
tions compared to adjacent normal breast tissue (270).
Hence, it is of interest that the highest incidence of breast
cancer is observed in postmenopausal women despite ces-
sation of ovarian estrogen synthesis and the consequent
drop in circulating estrogen concentrations. Estrogens can
still be produced in postmenopausal women by tissue-
specific local conversion of androstenedione to E1, and to
a lesser extent T to E2, by aromatase (271). However,
estrogens are sulfated by E1 sulfotransferase (SULT1E1)
and phenol sulfotransferase (SULT1A1), and this ac-
counts for the high circulating E1S concentrations ob-
served in postmenopausal women, with this E1S pool act-
ing as a reservoir for peripheral conversion to E1 by STS
(35).
Significant scientific discussion surrounds the relative
importance of the two primary pathways for active estro-
gen generation, E1S desulfation, and androgen aromati-
zation in hormone-dependent breast cancer. Whereas in-
creased aromatase protein expression parallels increased
intratumoral E2 concentrations (272), there is currently
limited support for STS expression directly correlating
with locally increased E2 concentrations. However, STS
activity can be 50–200 times higher than aromatase ac-
tivity in breast cancer tissue (273), and STS mRNA is fre-
quently detected in breast tumors, whereas aromatase lev-
els are relatively low (274). This suggests that STS, rather
than aromatase, may be the primary driver for local E1
production in hormone-dependent breast cancer (275,
276). Enzyme kinetic studies show that STS activity is
higher than aromatase not only in cancerous tissue but
also in normal breast (270). In addition to local estrogen
metabolism via STS and aromatase, serum estrogen levels
for E1, E1S, E2, and E2 sulfate (E2S) have been reported to
fall after surgical removal of STS-positive breast cancer in
postmenopausal women, implying an additional systemic
effect and indicative of the importance of STS activity in
forming active estrogens (17, 277).
In breast cancer, STS mRNA expression (278) and ac-
tivity (275) are higher in cancerous compared to normal
breast tissue, with elevated STS mRNA expression being
significantly associated with lymph node metastasis, his-
tological tumor grade (279), and poor prognosis (280).
Soft tissue breast cancer metastasis expresses higher STS
mRNA compared to primary tumors (281). Furthermore,
SULT1E1 expression, responsible for E1 sulfation, is de-
creased in breast cancer, with an inverse correlation be-
tween tumor histological grade and levels of intratumoral
SULT1E1 immunoreactivity (17, 282, 283). Thus, it is
possible that breast cancers favor local desulfation path-
542 Mueller et al Steroid Sulfation and Desulfation Endocrine Reviews, October 2015, 36(5):526–563
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 19 January 2016. at 09:16 For personal use only. No other uses without permission. . All rights reserved.
ways to increase E1 availability from high circulating E1S.
Subsequent E1 conversion, by 17HSDs (17HSD-1), po-
tentially results in E2 concentrations that are considerably
higher in breast cancer tissue compared to circulating lev-
els (284). Intriguingly, patients treatedwith the aromatase
inhibitor exemestane have elevated breast tumor STS and
17HSD-1 immunoreactivity, which both correlate neg-
atively with tumor Ki67 proliferation index (285). This
suggests a compensatorymechanismviaE1Sdesulfation in
response to local E2 depletion caused by aromatase
inhibition.
Surprisingly, however, there are no definitive studies
correlating breast intratumoral E1 and E2 concentration
and STS activity and expression. Haynes et al (286) have
Figure 5.
Figure 5. A, The balance between sulfation and desulfation strongly influences steroid hormone action. The nonsulfated steroid may exert its
biological effect by binding to its cognate nuclear receptor or may be downstream converted to more active steroids. Once sulfation occurs by one
of various sulfotransferases, solubility of the steroid is dramatically increased, facilitating renal excretion, but also circulatory transit fueling
peripheral desulfation and local steroidogenesis. Sulfation may also suppress or modify downstream conversion by masking one of several
functional groups; further sulfation steps may occur or sulfated steroids may exert biological effects directly. B, Dysregulation of sulfation and
desulfation pathways dramatically alters available active steroids. In disease, especially in cancer, SULT enzymes expression and thus activity are
decreased, whereas STS activity is elevated. This situation favors desulfation and therefore results in an elevated local synthesis of active steroids.
Furthermore, OATP expression is also elevated in many cancers, increasing the intracellular availability of sulfated steroids to STS action.
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shown that STS mRNA may be down-regulated in breast
cancer from both premenopausal and postmenopausal
women compared tomatched controls. Furthermore, they
suggest that no correlation was observed between intra-
tumoral E2 and STS mRNA expression, and there is lim-
ited evidence to support a role for STS in establishing in-
tratumoralE2 levels in thesepatients.However, they failed
to examine STS activity in these tissue samples, and it is
thought that post-translational modification of the STS
enzyme is more important in determining STS activity
than measuring STS mRNA expression levels alone (61).
Furthermore, these results are in sharp contrast to other
findings that show breast cancer patients have a signifi-
cantly longer disease-free survival if their STS mRNA lev-
els are low (278) and that STS protein expression corre-
lates with ER expression (287). Also, STS activity has
consistently been shown to be elevated in breast cancer
tissue (57, 269, 278, 288).
The regulatory mechanisms underlying increased STS
expression in breast cancer are not fully understood. Cur-
rent evidence suggests that inflammatory cytokines,
TNF and IL-6, increase STS activity (57, 61), although
this has been disputed by a study showing negative cor-
relation between TNF/IL-6 expression and STS expres-
sion in soft tissue breast cancer metastases and primary
tumors (281). Expression of tissue-specific transcripts of
STS may also be controlled by ER signaling in normal
and cancerous breast tissue (52); these studies also dem-
onstrated that ER-positive human breast cancer tissue
expresses more active STS isoforms that are up-regulated
by local E2 concentrations, thus promoting cancer pro-
gression (52). Supporting this, a recent study investigat-
ing 45 primary breast tumors showed that STS and
17HSD-1 expression correlateswith ERactivity, asmea-
sured by transfection using adenovirus vectors carrying an
ERE-tk-GFP reporter gene (287). Thus, ER activation is
important in regulating STS activity and subsequent E1
and E2 synthesis, although a full understanding of what
regulates STS and SULT1E1 expression and activity in
breast cancer remains to be elucidated.
But what of DHEAS desulfation and the subsequent
synthesis of T and dihydrotestosterone (DHT) in breast
cancer? Before aromatase action, desulfation of DHEAS
by STS generates androgens, and although androgens can
act as estrogen prohormones, they themselves may have a
role in breast cancer incidence, risk, and proliferation
(282, 289). Historically, androgens were given therapeu-
tically to breast cancer patients (290, 291) to improve
survival outcomes. However, patients suffered undesir-
able side effects such as hirsutism and amenorrhea.
Currently, controversy exists as to the significance of
androgenic effects in breast cancer, and therefore, by ex-
tension, the importance of local DHEA sulfation and des-
ulfation. Unlike estrogens, in normal breast androgens in-
hibit proliferation (292, 293). However, in breast cancer,
androgenic effects are complex andmost likely depend on
the differing intracrinology of different breast carcinomas
(see Ref. 294 for excellent review). A recent systematic
review exploring 19 studies with a total of 7693 women
found AR expression in 60.5% of breast cancers. AR ex-
pression was more common in ER-positive tumors
(74.8%) compared to ER-negative (31.8%), and patients
expressing AR had improved overall survival (295). This
would support the rationale for selective AR activation as
a potentially attractive therapeutic approach for breast
cancer.
Although circulating DHEAS concentration correlates
positively with breast cancer incidence in premenopausal
(296, 297) and postmenopausal women (298, 299), the
importance of androgen synthesis through DHEAS des-
ulfation via STS in breast cancer has not yet been fully
explored. Early studies showed that DHEAS caused pro-
liferation in T47D breast cancer cells, known to have STS
activity (300), even when cotreated with tamoxifen, im-
plying that androgens influence breast cancer prolifera-
tion through AR activation (301) and not just through
estrogenicmetabolites (302). However, other studies con-
test these facts, with some showing DHEA as antiprolif-
erative in MCF-7 (303) but not in MDA-MB-231 or
Hs578T cells (304).
In vitro (305) and in vivo (306) studies using STS in-
hibitors imply that the dominant effect of increased
STS activity in breast cancer is not inhibition of growth
by androgens, but rather estrogen-driven proliferation.
However, phase I clinical trials of Irosustat (STX64,
667Coumate), a potent STS inhibitor (307), in breast can-
cer patients demonstrated that blocking STS activity not
only significantly reduced circulating E1S, but also low-
ered plasma DHEA and androstenedione concentrations,
and if DHEA is indeed antiproliferative in breast cancer,
this may have unwanted consequences for this treatment
approach.
2. Prostate
Inmen, theprostate is themajorperipheral tissuewhere
STS activity contributes to the local synthesis of biologi-
cally active androgens. Unlike breast cancer, where a
higher exposure to estrogens is associated with increased
malignancy risk, prostate cancer incidence is not associ-
atedwith high circulating androgen concentrations (308).
Men with prostate cancer, who have been treated by cas-
tration, can be successfully treated further by adrenalec-
tomy (309). Although outdated, this approach works be-
cause the adrenals secreteDHEAS,which can be activated
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to the active androgens T and DHT in prostate tissue
(310).
Similar to breast cancer, STS activity has been detected
in normal (311) and cancerous (312) prostate tissues. Fur-
thermore, SULT1E1 (17) and SULT2B1 (313) mRNA are
also detected. The expression patterns of these enzymes
will therefore influence local estrogen and androgen syn-
thesis. The prostate cancer cell line LNCaP exhibits higher
STS activity than some breast cancer cell lines (176). STS
activity is alsopresent inDU-145andPC-3prostate cancer
cells and in humanprostate cancer biopsies (312).DHEAS
can be metabolized to DHEA in these cells, with this hy-
drolysis being blocked by the STS inhibitor oestrone-3-
O-sulphamate (314). DHEA inhibits, whereas T induces,
apoptosis in LNCaP cells under serum-deprived condi-
tions (315); this effect may be due to differing binding
affinities to the AR of these two steroids, leading to dif-
ferent coactivator/corepressor recruitment. With regard
to proliferation, administration of DHEAS to castrated
male rats increases ventral prostate and seminal vesicle
weights and increases circulating DHEA and DHT con-
centrations, with this effect abolished by STS inhibition
(316). However, DHEA alone has little effect on LNCaP
or LAPC-4 growth, unless they are cocultured with pros-
tate stromal cells (317, 318), suggesting that downstream
androgen biosynthesis fromDHEA requires both prostate
stromal and epithelial components. Intriguingly, in pros-
tate cancer patients treated with the nonspecific P450c17
inhibitor, ketoconazole, or the specific P450c17 inhibitor,
abiraterone acetate, significant (20 g/dL) circulating
DHEAS concentrations were still present, suggesting that
this could act as a depot for further downstream androgen
formation via desulfation andAKR1C3 action (319). Fur-
thermore, a reasonably substantial (2.0–2.5 ng/mL) con-
centration of DHTS circulates in men (320) and, similarly
to E1S in women, could act as a reservoir for peripheral
DHT synthesis. Indeed, prostate cancer patients exhibit
significantly elevated circulatingDHTandDHTS concen-
trations compared to aged-matched controls (321), sug-
gesting their importance in thismalignancy’s development
and a potential further role for STS in active androgen
formation.
Recently, a role for estrogen signaling in prostate can-
cer development, particularly through ER splice vari-
ants, has also been postulated (322), and evidence is grow-
ing thatERmaymodulate androgenactionand therefore
prostate cancer development (323). Men have significant
E1S concentrations in circulation (see Table 1). STS activ-
ity is present in healthy and malignant prostate tissue
(312), and prostatic E1S uptakemay increase during aging
(324). Furthermore, circulating E2 concentrations are el-
evated in patients with prostate cancer (325), suggesting
estrogenic influences on the incidence and development of
this malignancy.
Interestingly, SULT1B1, a sulfotransferase that can sul-
fate DHEA, is down-regulated in prostate cancer com-
pared to normal prostatic tissue (108). Knockdown of
SULT1B1 in LNCaP cells increases DHEA-induced pro-
liferation (326), implying that the STS/SULT1B1 ratio in
the prostate regulates DHEAS/DHEA-induced prolifera-
tion. This ratio is likely to be influenced by local inflam-
matory conditions, as shown by Suh et al (59) who as-
sessed whether TNF can induce STS expression; LNCap
and PC-3 cells up-regulated STS expression in a TNF
concentration and time-dependent manner. They further
demonstrated that at least part of this effect was via the
phosphatidylinositol 3 (PI3)-kinase/Akt pathway because
PI3-kinase inhibitors and AKT inhibitors suppressed STS
mRNA up-regulation induced by TNF. The same group
later examined PC-3 cells and found that IGF-2 increased
STS expression via the same PI3-kinase/Akt pathway
(327).
The fact that inflammation and cancer are often seen
together (328),with evidence linkingprostatitiswithpros-
tate cancer risk (329) and high TNF associated with
poorer prognosis with earlier onset of castration-resistant
prostate cancer (330), it is interesting to surmise that local
inflammatory conditions may impact on the balance of
sulfation and desulfation in prostate tissue to drive pro-
liferation. Intraprostatic hormonal dysregulation occurs
in benign prostate hyperplasia (BPH) with an increase in
active sex steroids. STS activity and tissue concentrations
of DHEA and E1 were found to be higher in BPH tissue
compared to circulating concentrations (331, 332). How-
ever, clinical evidence of an association between TNF,
DHEAS, and DHEA concentrations, and BPH and pros-
tate cancer progression is currently lacking.
3. Endometrium
Endometriosis is a common gynecological condition
defined as proliferation of ectopic endometrial tissue and
stroma, ie, in locations other than the uterus. It is associ-
ated with pelvic pain, dyspareunia, dysmenorrhea, and
infertility.Endometriosis is estrogen-dependentand there-
fore occurs in women of reproductive years (333). The
premenopausal endometrium undergoes a regular and
predictable sequence of proliferation and secretion fol-
lowed by menstruation. STS has been shown to have a
cyclical change in activity during themenstrual cycle, sug-
gesting that, in this tissue at least, it is regulated by hor-
monal factors as well as regulating local estrogen and an-
drogen synthesis (334). In human endometrial tissue, STS
activity peaks at the early secretory stage and declines
thereafter (335). IL-1, known to increase at the secretory
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phase of menstruation, suppresses STS mRNA and activ-
ity in human endometrial stromal cells (336). STS activity
is also elevated in ovarian and rectovaginal endometriosis
compared to disease-free endometrium with enzyme ra-
tios (STS/SULT1E1 and HSD17B1/HSD17B2), favoring
E2 production (337). Indeed, SULT1E1 protein has been
shown to be down-regulated in human endometriosis tis-
sue (338), and increasing STS activity correlates with dis-
ease severity (339). Not all studies have shown this cor-
relation, but STS activity is consistently high in eutopic
and ectopic endometrial tissue (340). STS inhibitors re-
duce STS activity in endometriotic implants (341), and
inhibition of STS in murine models of endometriosis de-
creases disease severity (342). Interestingly, randomized,
double-blind, placebo-controlled trials examining com-
bining E2MATE, an STS inhibitor, with norethindrone
acetate, a synthetic progestin, demonstrated a synergistic
effect on STS inhibition, suggesting this approach as a
potential treatment option for endometriosis patients
(343).
Increased STS activity and expression are also associ-
ated with endometrial cancer. Both nuclear ERs are ex-
pressed in the endometrium, with ER more highly ex-
pressed than ER. Data on ER expression alterations in
both endometriosis andendometrial cancer are conflicting
(344–346). However, as with breast and colorectal can-
cer, estrogen levels have been shown to be higher in en-
dometrial tumor tissue compared tonormal,withE2 tissue
levels correlating positively with disease stage and tumor
invasion (347). Prolonged lifetime estrogen exposure and
reproductive factors such as early menarche, nulliparity,
and late menopause increases the risk of endometrial can-
cer (348–350). Hormone replacement therapy (HRT) can
increase the risk of endometrial cancer because estrogens
stimulate proliferation in the endometrium, unless it is
combinedwith progesterone therapy, as this hormone dif-
ferentiates endometrial cells.
Despite endometrial cancer being estrogen driven, par-
adoxically and similar to breast cancer, the greatest inci-
dence is in postmenopausal women (351), again indicat-
ing peripheral estrogen synthesis. Although aromatase
activity is not present in endometrial tissue (352), STS
activity is increased up to 12-fold in human endometrial
cancer tissue (353, 354). Utsunomiya et al (355) found
86% of endometrial tumors immunoreactive for STS and
29% for SULT1E1. The STS/SULT1E1 ratio correlated
with poorer prognosis, with a higher ratio associatedwith
high circulating E2 levels. Of note, Lukanova et al (349)
showed that elevated circulating estrogens and androgens
were associated with endometrial cancer risk. They hy-
pothesized that although serum androstenedione and T
positively correlated with endometrial cancer risk, it can-
not be concluded whether this is mediated primarily
through estrogen conversion or by AR activation. Thus,
attenuating both estrogenic and androgenic sex steroids
throughSTS inhibitionappears tobe a feasible therapeutic
strategy in endometrial cancer.
The endometrial cancer cell lines Ishikawa, HEC-1A,
HEC-1B, and RL-95 do not metabolize androstenedione
to E1 or E2, suggesting that aromatase is not important in
these cells (356).However, E1S is hydrolyzed in these cells,
albeit at a low rate, and an in vivo Ishikawa xenograft
model in mice has demonstrated that endometrial cancer
proliferation can be driven by E1S and inhibited by STS
inhibitors Irosustat and STX213 (357). Unfortunately,
phase II trials of Irosustat as a monotherapy in endome-
trial cancer patients were discontinued in 2011 after data
indicated no beneficial effect of STS inhibitionwhen com-
pared to megestrol acetate. However, future studies will
examine the effects of combining STS inhibitionwith stan-
dard treatment options for endometrial cancer patients.
4. Colorectal
Colorectal cancer (CRC) is not routinely referred to as
hormone sensitive; however, estrogens and androgens are
implicated in both normal gastrointestinal physiology and
carcinogenesis (358). Evidence supports a role for estro-
gens not only inCRCpathogenesis, but also in protection.
This dual role of active estrogenswas first postulated from
the Women’s Health Initiative (WHI) study that demon-
strated combination (equine E1S plus progestins) HRT
resulted in 40% CRC risk reduction, suggesting that es-
trogen or progestins may have protective roles. The com-
bined oral contraceptive pill also reduced CRC risk by
20% (359). However, women diagnosed with CRCwhile
usingHRThadhigher tumorgrades, suggesting either that
HRT delayed clinical diagnosis or that estrogens also play
a role in tumor progression (360). A large study by Zer-
voudakis et al (361) explored the association between life-
time endogenous estrogen and CRC, finding that higher
exposure increased risk in postmenopausal women. Con-
tradictorily, as a population,males are at an increased risk
of CRC, in particular compared to premenopausal
women. Younger women also have an improved survival
(362), suggesting that the relationship between estrogens
and CRC incidence is complex.
Estrogen concentrations, as measured by LC-MS, are
higher in human CRC tissue compared to normal colonic
mucosa, and when separated into E1 and E2, E1 concen-
trations predominated (363), suggesting high CRC intra-
tumoral E1S desulfation. High local total estrogen (E1 and
E2) concentrations are associated with reduced CRC sur-
vival (337). Interestingly, estrogen concentrations are con-
cordant with high STS and low SULT1E1 expression
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rather than aromatase, and the STS/SULT1E1 ratio cor-
relates with prognosis; ie, patients with tumors negative
for STS and positive for SULT1E1 had an improved out-
look, whereas those positive for STS and negative for
SULT1E1 were associated with unfavorable clinical out-
come. Thus, estrogens generated through STS appear to
contribute to CRCprogression and poor survival. English
et al (364, 365) also found STS activity to be increased in
CRC tumors, and additionally 17HSD-2 protein expres-
sion was frequently reduced with no alteration in aroma-
taseactivity; thus, increasedE1generatedviaSTS, together
with a fall in 17HSD-2, should drive production of bi-
ologically active E2.
The evidence for DHEAS andDHEA in CRC incidence
and proliferation is more obscure. Debate exists on
whether there is any significant aromatase activity in the
colon (358, 364) and, if it is present, whether it affects
clinical outcomes (366). Therefore, local DHEAS desul-
fation would mostly be utilized for androgen production,
and functional membrane ARs are present in colonic tu-
mors (367). However, the effect of androgens in CRC is
unclear. In vitro T induced apoptosis in CRC cell lines
(315, 368), whereas DHEA enhances survival (315). In
contrast, Tutton and Barkla (369) found that in vivo ad-
ministration of T accelerated cell proliferation in the small
intestine and induced colon cancer in rats, with CRC
growth reduced after castration. This early study has been
strongly supported recently by elegant studies demon-
strating that T and DHT promote the development and
proliferation of colon adenomas in rats andmice, whereas
castration markedly protected colon adenoma formation
(370).
In humans, studies exploring the effect of androgen
treatment on the colon have been inconsistent. Alberg et al
(371), examining serum from CRC patients, found that
higher circulating DHEAS concentrations in men were
slightly associatedwith a decreased risk of CRC. Support-
ing this finding, a large study of 107 859 prostate cancer
patients explored CRC incidence and androgen depriva-
tion therapy (372). Initial results showed orchiectomy
caused the highest incidence of CRC, followed by GnRH
agonist therapy and men with no androgen deprivation
therapy. CRC risk increased with the length of time a pa-
tient was subjected to androgen deprivation therapy
(373), and thus androgens may act like estrogens with
both protective and cancer-promoting effects in the con-
text of CRC.
B. Aging
Serum DHEA and DHEAS decline with age, and at 70
years of age, circulating DHEAS concentrations have di-
minished by 90% compared with the peak levels achieved
at ages20–30 (374).Thus, there iswidespread speculation
about a causative role of DHEAS in age-related disease
development and human longevity. In cross-sectional
studies, lowDHEAandDHEAS concentrations have been
associated with geriatric syndromes, such as sarcopenia
(375, 376), poor cognitive function (377), depression
(378), cardiovascular disease (379), erectile dysfunction
(380), and low sexual drive (381). Little is known about
what triggers the gradual decline of DHEA and DHEAS,
but because it accounts for 50% of androgens in men and
75% of estrogens in premenopausal women (382), delin-
eating this effect is of significant importance in age-related
research.
It is most likely that declining DHEA and DHEAS con-
centrations are associatedwith decreased adrenal produc-
tion, rather thananalteration inDHEAmetabolism (383).
However, some evidence suggests that a relationship be-
tween DHEAS and DHEA is defined by activity of
SULT2A1, the enzyme that converts DHEA to DHEAS
(223), and that impairment ofDHEA sulfation causes low
DHEASand concurrent androgen excesswith highDHEA
and androstenedione concentrations (237). Genetic vari-
ants of SULT2A1 do not appear to have an effect on in-
dividual DHEA and DHEAS concentrations or the
DHEA/DHEAS ratio as a marker of DHEA sulfonation
capacity (249). However, to date, no other research has
been published on aged-induced alterations in SULT2A1
and STS activity, particularly in the adrenal gland; thus,
conclusions on potential mechanisms behind the age-as-
sociated decline in DHEA and DHEAS are lacking.
VII. Pharmacological Intervention
A. STS inhibitors
Clearly, the ability to pharmacologically target STS has
significant potential in a number of disease states. In can-
cer, where the desulfation of E1 and DHEA may play im-
portant roles in breast and prostate cancer, STS inhibitors
may show significant promise (269). Furthermore, steroid
dynamic studies reveal that DHEA andDHEAS can act as
precursors for the formation of other steroids with estro-
genic and androgenic properties, such as 5-androstenediol
(Adiol). Evidence suggests that DHEAS (301) and Adiol
(384) stimulate breast cancer cell proliferation in vitro,
although other contradictory evidence suggests that
DHEA may play a protective role against the disease
(304,385). Interestingly, DHEAS concentrations in
plasma are very high (Table 1); it is the most abundant
steroid secretedby the adrenal cortex. Similar toE1S, it has
a long plasmahalf-life (10–20h), significantly longer than
the unconjugated DHEA (386, 387). After hydrolysis via
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STS, DHEA undergoes further reduction to Adiol, an an-
drogen steroid able to bind to the ER and cause mitogen-
esis (388). Therefore, due to the large plasma concentra-
tions of the precursors ofAdiol, this STS-affected pathway
mayplay an important role in cancer tumorigenesis. Thus,
inhibiting STS should not only block E1 synthesis, but also
significantly limit androgen precursors. Indeed, in the first
phase I clinical trial of an STS inhibitor, circulating an-
drostenedione and T were significantly decreased in post-
menopausal women with refractory hormone-dependent
breast cancer (307). There have been several recent com-
prehensive and excellent reviews covering the develop-
ment of STS inhibitors for various hormone-dependent
malignancies (269, 389–391); thus, this section will only
briefly examine and summarize the current status of STS
inhibitor development.
The first STS inhibitor to demonstrate hepatic in vivo
activity in a rat model was 667Coumate (STX64, Irosus-
tat), a potent tricyclic coumarin-based sulfamate that ir-
reversibly inhibits STS (392). This compound has shown
excellent in vivo efficacy against E2S-driven breast cancer
(393, 394) and endometrial cancer (357) and has shown
promise in phase I clinical trials in female patients with
hormone-dependent breast cancer (307). Currently,
667Coumate undergoes evaluation in hormone-depen-
dentbreast cancerpatients in combinationwitharomatase
inhibitors in phase I/II trials, and results should be pub-
lished in late 2015.
The first-in-class successof667Coumatehasnotdamp-
ened enthusiasm for further development of novel STS
inhibitors. Recently, for example, several groups have de-
velopedderivatives ofE1 sulfamate (395), 4-substitutedE1
and E2 (396), and 17-arylsulfonamides of 17-aminoes-
tra-1,3,5(10)-trien-3-ol (397).Others are investigating the
potential for dual-acting compounds that target both STS
and ER (398) or STS and aromatase (399), and second-
generation STS inhibitors have been shown to be effective
against E2S-stimulated breast cancer in vivo (393). Re-
cently, a compound,EM-1913, has shownefficacy against
DHEAS desulfation and therefore inhibits effects in an-
drogen-sensitive tissues (316).
B. Modulation of sulfation
All human sulfotransferases need the atypical nucleo-
tide PAPS as an active sulfate donor, and PAPS binding is
highly conserved between distantly related members of
this large gene family. Because PAPS has an adenosine
moiety, kinase-directed and purine-based compound li-
braries have been used in the past to discover sulfotrans-
ferase inhibitors (400–402). To develop SULT isoform-
specific inhibitors, bisubstrate analog-based approaches
have been applied to various sulfotransferases (403, 404).
Although these early studies have aimed at cytosolic sul-
fotransferases,more researchactivitymayhavebeen spent
on heparan and chondrocyte sulfotransferases (80,
405–407).
The rate-limiting step for all sulfation reactions is pro-
vision of active sulfate in the form of PAPS, and the re-
sponsible PAPS synthases are recognized as fragile en-
zymes stabilized by the APS intermediate of PAPS
biosynthesis (70, 72). APS interacts both with the sulfu-
rylase and APS kinase domain and effectively suppresses
PAPSS2 aggregation at low micromolar concentrations
(72). Exploiting this principle of action for compound de-
velopment may result in PAPS synthase-stabilizing com-
pounds that may increase overall sulfation capacity.
VIII. Future Directions
Historically, steroid sulfation was regarded as a mecha-
nism to facilitate steroid circulatory transit and renal ex-
cretion.Researchover thepast fewdecades challenged this
view because it became clear that circulating steroid sul-
fates (ie, DHEAS) are desulfated and thus act as a systemic
reservoir for peripheral metabolism. This is especially im-
portant because peripheral or local steroidogenesis can
thus occur in otherwise nonsteroidogenic tissues (ie, de-
void of the P450 side chain-cleaving enzyme P450scc),
such as the brain or in prostate cancer (408). Sulfation and
desulfation represent a dynamic way of balancing the
availability of free steroid hormones near target sites;
however, these processes need to be tightly controlled in
cells where steroid sulfotransferase and sulfatase are co-
expressed to avoid a vicious cycle.
This reviewhasmade clear that steroid hormone action
strongly relies on the intricate interplay of sulfation and
desulfation processes as well as membrane transport of
sulfated steroids. Studies simultaneously looking at all
three of these processes are still lacking; there are no clear
data on the factors that regulate these pathways, and sub-
sequently their importance in many pathologies has most
likely been overlooked. It is clear that the ratios between
STS and SULTswill have profound consequences on local
steroid metabolism, but research into how these ratios
impact upon normal and diseased tissue remains to be
done.
It would be of great interest to map the relative con-
centrations of sulfated and desulfated steroids in a tissue-
specific manner under various physiological states.
Whether MS imaging (409) may turn out to be useful in
this regarddependsonwhen itwill reach spatial resolution
on a single cell level. Furthermore, the accurate measure-
ment of the intracellular fluctuations of both sulfated and
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nonsulfated steroids in both normal and pathological
states would provide significant insights into STS, SULT,
and OATP biology.
Furthermore, the direct biological effects of steroid sul-
fates are the subject of lively scientific debate. E1S may
elicit biological effects inuterine endometrium that are not
seenwith E2 (15). As a neurosteroid, pregnenolone sulfate
clearly exerts different effects than its nonsulfated coun-
terpart, pregnenolone. Although unconjugated preg-
nenolone is a barbiturate-like agonist, pregnenolone sul-
fate can bind to and suppress the gamma-aminobutyric
acid receptor acting as a picrotoxin-like antagonist (410).
It is difficult to dissect the molecular roles of DHEA and
its sulfate ester, DHEAS. Experimentally, it is challenging
to discriminate between direct DHEAS effects and those
caused by desulfation and downstream conversion to
more potent androgens and estrogens. DHEAS has been
reported to induce transcription of the abundant miR-21
in liver cell lines; however, this effect is clearly linked to
both desulfation and conversion to more potent andro-
gens and estrogens (411). Evidence accumulates that
DHEAS may have physiological roles of its own—as a
neurosteroid acting antagonistically to DHEA (408); it
has a hormone-like activity on the spermatogenic GC-2
cell line by activating a G11-receptor (412) and has been
shown to directly activate protein kinase C in human
neutrophils (413).
Pharmacological intervention on sulfation and desul-
fation pathways remains in its infancy. Although prom-
ising progress has been made with regard to STS inhibi-
tion, few pharmacological tools exist to selectively target
individual SULTs or OATPs. The development of these
inhibitors would not only be a boon for basic researchers
but also would allow for the potential development of
future drugs targeting sulfation/sulfate transportation,
many of which are up-regulated in various pathologies.
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